Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment for severe low blood sugar levels (hypoglycaemia) in diabetics ...

Eli Lilly’s intranasal formulation of glucagon – called Baqsimi – is the first alternative to injectable glucagon for severe hypoglycaemia, which typically occurs when people with diabetes ...

The introduction of Primatene Mist ($26.1 million), Baqsimi ($40.4 million), and Albuterol ... powering earnings growth.” Eli Lilly and Company (NYSE:LLY) tops our list for being one of the ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...

The most recent trading session ended with Eli Lilly (LLY) standing at $827.54, reflecting a +1.16% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 2.51%.

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the ...